Neural Correlates In Mild Alzheimer's Disease

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to identify neural correlates of cognitive improvement after three months of donepezil HCl in subjects with mild Alzheimer's Disease (AD), measuring the Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion in the Medial Temporal Lobe network. The hypothesis is that donepezil HCl will improve MTL connectivity and CBF Perfusion in the MTL-projected target regions, which will significantly correlate with cognitive improvement in mild AD subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Inc.
• Collaborator: Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Men and women, aged 50 and older with mild Alzheimer's disease (MMSE scores of 20 to 30 are allowed).

• Diagnostic evidence of Alzheimer's disease.

• Previous use of cholinesterase inhibitors (other than Aricept) and memantine allowed.

Exclusion Criteria:

• Prior use of Aricept, pacemakers and insulin dependent diabetes are not allowed.